BeOne Medicines (BEIGF) EBT (2015 - 2026)

BeOne Medicines (BEIGF) has reported EBT for 12 consecutive years, with $312.5 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, EBT rose 213.87% year-over-year to $312.5 million in Q2 2026; TTM through Jun 2026 was $868.1 million, a 1473.41% increase from a year earlier, with the FY2025 full-year figure at $416.9 million, up 178.21% from the prior year.
• EBT was $312.5 million for Q2 2026 at BeOne Medicines, up from $259.2 million in the prior quarter.
• Over five years, EBT peaked at $312.5 million in Q2 2026 and troughed at -$557.6 million in Q2 2022.
• A 5-year average of -$129.5 million and a median of -$102.1 million in 2024 frame the typical range for EBT.
• Across the five-year window, EBT tumbled 780.92% in 2022 and jumped 1140.26% in 2026, its largest moves.
• Over 5 years, EBT stood at -$431.0 million in 2022, then rose by 18.61% to -$350.8 million in 2023, then surged by 75.67% to -$85.4 million in 2024, then soared by 274.86% to $149.2 million in 2025, then surged by 109.37% to $312.5 million in 2026.
• The last three EBT figures came in at $312.5 million (Q2 2026), $259.2 million (Q1 2026), and $149.2 million (Q4 2025), per Business Quant data.